Grant Knappe is developing a drug delivery technology platform based on nucleic acid nanoparticles to address the current limitations of commercial delivery technologies. Nucleic acid nanoparticles have several features amenable to therapeutic delivery, including biocompatibility, biodegradability, and incorporation of targeting ligands and therapeutic cargos. Grant is optimizing this platform for the delivery of nucleic acid therapeutics toward treating many diverse diseases.

Grant is a PhD candidate in the Department of Chemical Engineering at MIT, conducting his doctoral research under the advisement of Professor Mark Bathe as an MIT Presidential Fellow and an NSF Graduate Research Fellow. Grant received a BS in chemical engineering from the University of Delaware, where he researched new polymer chemistries and architectures in Professor Christopher J. Kloxin’s laboratory.